Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Gdansk – page 29

865 clinical trials in Gdansk, Poland across 11 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gdansk at a glance
865
clinical trials
  • Research sites11
Type of trial
Recruitment status
Quick filters

865 trials in Gdansk

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not yet recruiting

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer

Not yet recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Acne

Not yet recruiting

Safety and Efficacy Study of the Acne mRNA vaccine (mrt1800, mrt1801, mrt1802) in Adults 18‑45 Years with Moderate to Severe Acne

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Sponsor:Sanofi Vaccines US Inc.

Plasma cell myeloma

Not yet recruiting

Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Polish Myeloma Consortium

Relapsing multiple sclerosis+1

Not yet recruiting

Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous Ocrelizumab in Children and Adolescents with Relapsing‑Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Major depression

Not yet recruiting

Long‑Term Safety, Tolerability and Efficacy of Azetukalner in Patients with Major Depressive Disorder

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Infection prophylaxis

Not yet recruiting

Study of human normal immunoglobulin to prevent major infections in patients with hypogammaglobulinemia and autoimmune/rheumatic disease on B‑cell depletion therapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Dermatitis atopic

Not yet recruiting

Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

Parkinson's disease

Not yet recruiting

A study to optimize the delivery of AAV2-GDNF and gadoteridol into the brain for patients with Parkinson's disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteridol
  • Sponsor:Askbio Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gdansk

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on bladder cancer, lymphoma, and various advanced solid tumors. Studies are evaluating novel combination therapies and investigating treatments for non-small cell lung cancer.

  • Bladder Cancer Immunotherapy
  • B-Cell Lymphoma Treatment
  • Gastric Cancer Therapeutics

Research includes promising approaches combining established treatments with new immunotherapy agents.

02 Dermatology Studies

Clinical investigations targeting plaque psoriasis, genital psoriasis, and atopic dermatitis. Studies are examining oral and subcutaneous treatments for moderate to severe skin conditions.

  • Psoriasis Management
  • Hidradenitis Suppurativa
  • Novel Dermatological Therapies

Focus on developing targeted treatments for chronic skin conditions affecting quality of life.

03 Metabolic Disorders

Comprehensive research into obesity and weight management, including studies for patients with and without type 2 diabetes. Trials are evaluating new therapeutic approaches for weight reduction.

  • Weight Management Solutions
  • Diabetes Treatment
  • Cardiovascular Risk Management

Investigation of innovative treatments combining lifestyle modifications with pharmaceutical interventions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.